VALPROIC ACID (DEPAKINE)

The VALPROIC ACID (DEPAKINE) home blood test measures serum valproic acid concentration and includes key liver and kidney function markers to ensure safe and effective therapy. A trained phlebotomist collects a venous blood sample at home across Dubai and the UAE, and samples are analyzed in accredited laboratories to assess therapeutic levels and organ safety. Regular monitoring helps prevent subtherapeutic dosing that can lead to breakthrough seizures and detects early signs of toxicity such as hepatotoxicity, hyperammonemia, or renal impairment.

This test is recommended for patients receiving valproate for epilepsy, bipolar disorder, or migraine prophylaxis when dose titration, compliance checks, or safety monitoring are needed. It is especially useful for children, the elderly, patients with pre-existing liver or renal disease, those on multiple interacting medications, and women of childbearing potential where therapy decisions require careful balancing of benefit and risk.

For accurate interpretation, a trough sample taken immediately before the next scheduled dose (commonly ~12 hours after the last dose for twice-daily regimens) is preferred; fasting is generally not required. Results typically include serum valproic acid level plus liver (ALT, AST, bilirubin) and renal (creatinine, urea) markers; abnormal findings should be reviewed by the treating clinician who may adjust dosing, request additional tests (e.g., CBC, ammonia), or provide urgent management.

• Valproic Acid (Serum) Level
• Alanine Aminotransferase (ALT)
• Aspartate Aminotransferase (AST)
• Total Bilirubin
• Serum Creatinine
• Blood Urea (Urea)

• After initiating or changing valproate dose
• To achieve or confirm therapeutic drug levels
• When signs of toxicity appear (excessive sedation, tremor, vomiting, confusion)
• Routine periodic safety monitoring of liver and kidney function
• Before conception, during pregnancy planning, or if pregnancy is suspected

• Ensures valproic acid is within the therapeutic range
• Early detection of hepatotoxicity and jaundice risk
• Monitors renal function to detect impairment early
• Supports safe dose adjustments and improves treatment adherence
• Convenient at‑home sample collection across Dubai and the UAE with accredited lab reporting

• At‑home venous blood collection by a trained phlebotomist
• Trough sample—collect immediately before the next scheduled dose (commonly ~12 hours post‑dose)
• No fasting usually required unless instructed by your physician
• Notify the team of all medications, supplements, recent dose changes, and pregnancy status